Can Postmenopausal HRT Increase Blood Pressure?
Yes, postmenopausal HRT can modestly increase blood pressure, but the effect depends critically on the formulation used—oral conjugated equine estrogens (CEE) with progestogen increase systolic blood pressure and hypertension risk, while transdermal estradiol-based regimens appear neutral or may even reduce blood pressure.
Evidence-Based Breakdown by Formulation
Oral Conjugated Equine Estrogens (CEE) + Progestogen
The largest and highest quality evidence comes from the Women's Health Initiative (WHI), which found 1:
- Average 1 mm Hg increase in systolic blood pressure over 5.6 years in 8,506 women using CEE plus medroxyprogesterone acetate
- 25% greater likelihood of developing hypertension compared to non-users in cross-sectional analysis of nearly 100,000 women
- No significant effect on diastolic blood pressure
A 2024 meta-analysis confirms this, showing oral CEE plus progestogen specifically increases systolic blood pressure (SMD = 0.60 mm Hg) 2. An Australian cohort study of 43,405 women demonstrated increased odds of hypertension with past MHT use, with effects strongest in younger postmenopausal women and increasing with duration of use 3.
Transdermal Estradiol ± Progestogen
The evidence strongly favors transdermal preparations 2, 4, 5, 6:
- No significant blood pressure increase with transdermal estradiol plus progestogen (SMD = -2.00 mm Hg, 95% CI = -7.26 to 3.27)
- Multiple 24-hour ambulatory blood pressure studies show blood pressure reductions in 11 of 13 studies using transdermal estradiol
- One study of 1,397 hypertensive women using transdermal HRT showed average reductions of 7 mm Hg systolic and 9 mm Hg diastolic 4
Oral Estradiol-Based Regimens
Oral estradiol (not CEE) plus progestogen, estradiol alone, and tibolone showed no significant blood pressure effects 2, 5.
Clinical Algorithm for HRT and Blood Pressure Management
For normotensive women considering HRT:
- Prefer transdermal estradiol-based preparations over oral CEE formulations
- Monitor blood pressure closely at initiation, then at 6-month intervals 1
For hypertensive women considering HRT:
- Transdermal estradiol is the preferred formulation given neutral-to-beneficial blood pressure effects 4, 5, 6
- Oral CEE formulations should be avoided due to increased hypertension risk
- Blood pressure should be monitored closely at first, then at 6-month intervals 1
- Among progestins, drospirenone (spironolactone-derived) has the best antihypertensive properties 6
For women already on oral CEE-based HRT:
- Monitor blood pressure every 6 months
- Consider switching to transdermal estradiol if blood pressure increases
- Discontinuation may actually increase hypertension risk in some women 7
Important Caveats
The Formulation Matters More Than "HRT" as a Class
The JNC-7 guidelines appropriately conclude that "HRT-related change in BP is likely to be modest and should not preclude hormone use in normotensive or hypertensive women" 1. However, this statement predates the 2024 meta-analysis showing clear differences between formulations 2. The type of estrogen (CEE vs. estradiol) and route of administration (oral vs. transdermal) are critical determinants of blood pressure effects.
Conflicting Evidence Explained
Smaller observational studies (Baltimore Longitudinal Study on Aging, Postmenopausal Estrogen/Progestin Intervention trial) showed either beneficial or neutral effects 1, 8. These discrepancies likely reflect:
- Different formulations studied (many used estradiol rather than CEE)
- Selection bias in observational studies
- The WHI remains the gold standard with its large randomized design
The Effect is Modest but Clinically Relevant
While the absolute blood pressure increase with oral CEE is small (1 mm Hg systolic), the 25% increased likelihood of developing hypertension is clinically significant given hypertension's impact on cardiovascular morbidity and mortality 1.
Potential Benefits on Circadian Blood Pressure
Some studies suggest HRT may restore normal nighttime blood pressure "dipping" that diminishes in postmenopausal women, potentially reducing target organ damage despite modest daytime increases 1. However, this benefit appears more consistent with transdermal preparations.
Bottom line: Hypertension should not be considered an absolute contraindication to HRT, but formulation selection matters—choose transdermal estradiol-based regimens for hypertensive women and monitor blood pressure regularly regardless of formulation used.